INTRODUCTION
The human genome encodes z70 Rho guanine exchange factors (GEFs) involved in the catalytic stimulation of Rho guanosine triphosphatases (GTPases). This drug-targetable activity, together with the key roles played by Rho GTPases in cancer-related processes, has led to the consideration of these enzymes as potential drug targets. Reinforcing this view, studies using cell lines and animal models have clearly established direct connections between Rho GEF activity and protumorigenic events (Vigil et al., 2010) . Despite this evidence, the structural and functional complexity of these proteins indicates that the univocal relationship between Rho GEF activity and protumorigenic functions might not always occur. In this context, some features of these pathways suggest that, at least theoretically, some Rho GEF subsets could antagonize cell transformation. Thus, the discovery of loss-of-function RHOA gene mutations in human tumors suggests the possibility that RhoA-specific GEF subsets could exert suppressor roles in cells that have not yet acquired those mutations (Zandvakili et al., 2017) . The same concept applies to GEFs that stimulate RhoB, a GTPase with tumor-suppressing activities (Vigil et al., 2010; Zandvakili et al., 2017) . Given their multidomain structure, it is also possible that GEFs could promote tumor-suppression pathways via GTPase-independent mechanisms.
Significance
Rho GEFs, including Vav1, are traditionally regarded as protumorigenic elements in tumors. Contrary to this paradigm, we demonstrate here that Vav1 can perform tumor-suppressor functions in immature T cells. This catalysis-independent activity depends on the formation of Vav1-Cbl-b-ICN1 complexes that facilitate the Cbl-b-mediated degradation of ICN1. This pathway is active in many T-ALL cell lines regardless of the mutational status of Notch1. We also show that the repression of this tumor-suppressor pathway by transcriptional factors of the TLX family is required for the fitness of human TLX + T-ALL. These data challenge the concept of the monodimensional implication of Rho GEFs in protumorigenic pathways, unveil a function for Vav1, and provide insights into human TLX + T-ALL pathogenesis.
Vav1 is a hematopoietic-specific GEF that epitomizes the structural and functional complexity of the Rho GEF family. Thus, it harbors calponin-homology (CH), acidic (Ac), catalytic Dbl-homology (DH), pleckstrin-homology (PH), zinc-finger (ZF), SH2, and SH3 domains that have regulatory (CH, Ac, SH2, SH3), catalytic (DH, PH, ZF regions), and adaptor (CH, SH3) functions. As a result, Vav1 can engage catalysis-dependent and -independent pathways during cell signaling (Bustelo, 2014) . Extensive genetic evidence using both cell lines and knockout mice support the implication of Vav1 in cell transformation. In fact, its discovery was possible due to the transforming activity displayed by an oncogenic mutant version in focus formation assays (Bustelo, 2014) . Its connection with protumorigenic events has been further reinforced by the recent discovery of potential VAV1 gain-of-function mutations in adult T cell leukemia and lung tumors (Abate et al., 2017; Boddicker et al., 2016; Campbell et al., 2016; Kataoka et al., 2015) . However, contrary to this canonical view, it has been observed that the loss of Vav1 favors the progressive emergence of T cell tumors in aging mice (Ruiz et al., 2009 ). The cause of this unexpected phenotype remains unknown.
The Notch1 pathway is frequently involved in human T cell acute lymphoblastic leukemia (T-ALL). The ADAM and g-secretase proteases cleave this receptor in a ligand-dependent manner under physiological conditions, leading to the release of its cytoplasmic ICN1 tail. ICN1 then translocates to the nucleus, interacts with RBPJk, and stimulates expression of cell fate-, metabolic-, and proliferation-related genes. This transcriptional program is eventually shut down by ICN1 degradation, a step regulated by the E3 ubiquitin ligase Fbxw7. This tight regulation is frequently lost owing to gain-and loss-of-function mutations in NOTCH1 or FBXW7 genes in T-ALL, respectively (Van Vlierberghe and Ferrando, 2012) . However, these mutations seem to require additional genetic lesions to drive T-ALL, including gain-of-function alterations in transcriptional factors such as LYL1, HOXA, TAL1, TLX1, and TLX3 (Van Vlierberghe and Ferrando, 2012) .
We have recently found that carcinogen-exposed young Vav1 À/À mice develop quite aggressive early cortical T-ALL with very short latency periods. The investigation of this rather paradoxical effect led us to discover a Vav1-dependent tumorsuppressor pathway involved in ICN1 regulation in immature T cells.
RESULTS
The Vav1 Gene Deficiency Promotes Immature T Cell Tumors in Mice While addressing the role of Vav proteins in tumorigenic processes, we found that Vav1 À/À mice become sick quite rapidly upon the administration of carcinogens such as 7,12-dimethylbenz [a] anthracene (DMBA), N-nitroso-N-methylurea, and urethane ( Figure 1A , data not shown). As a result, Vav1-deficient mice become terminally ill 10-12 weeks after exposure to the carcinogen ( Figure 1A ). Necropsies revealed the presence of highly enlarged thymi lacking the typical bilobular morphology ( Figure S1A ). These thymi also displayed effaced corticomedullary boundaries ( Figure S1B ), an increase in thymus weight ( Figure S1C ), and a ''starry night'' histology characterized by the presence of macrophages containing large numbers of engulfed dead cells ( Figure S1B ). This phenotype is exclusively driven by Vav1 deficiency since compound Vav1 Figure 1D ). Consistent with this, they lack intracellular (ic) and membrane expression (m) of the T cell receptor (TCR) b subunit ( Figure 1E ). CD8 + tumor cells are CD24 + ( Figure 1F ), icTCRb + , and mTCRb -( Figure 1G ), thus indicating that they derive from the abnormal expansion of immature single CD8-positive (ISP) cells ( Figure 1H ). The DN and CD8 + tumor populations differ in their ability to disseminate outside the thymus, since we could only find peripheral cancer cells at high frequency (45% of cases, n = 45) in CD8 + tumor-bearing animals ( Figures 1C, S1E , and S1F). Similar immunophenotype distributions were observed in tumors from N-nitroso-N-methylurea-and urethane-treated Vav1 À/À mice (data not shown).
The DMBA-induced tumors develop very quickly in Vav1 À/À mice, as assessed by the detection of abnormally expanded DN ( Figure S2A ) and CD8 + ( Figure S2B ) populations as early as 1 week after ending the DMBA treatments in z35% of all the animals surveyed ( Figure S2C ). This phenotype reached a penetrance of 70% and 100% 4 and 12 weeks later, respectively (Figure S2C ). The effect of the growth of these tumor cells in the overall size of the thymus ( Figures S2D and S2E ) and number of thymocytes ( Figure S2F ) is also apparent 4 weeks after finishing the carcinogenic treatment. DMBA-exposed WT mice develop T cell tumors with longer latencies and lower frequencies ( Figure 1A ). These tumors are CD8 + CD24 + icTCRb + cells and harbor a significant pool (z30%) of mTCRb + cells (Figures 1C and S2G) . Taken together, these results indicate that Vav1 acts as a tumor-suppressor gene at the DN1-DN2 and ISP T cell developmental stages ( Figure 1H ). It is unlikely that this is a reflection of a canonical function, since the known Vav1 GEF and adaptor activities are associated with thymocyte selection events taking place at the DN and CD4 + CD8 + differentiation stages and, later on, with the antigenic responses of mature T cells ( Figure 1H ).
Vav1
-/-Tumors Show Notch1-like Functional Signatures
À/À tumor cells exhibit large transcriptional changes that involve the deregulation of ''common'' ( Figure 2A and Table  S1 ), DN-specific (Table S1) , and CD8 + -specific (Table S1 ) gene sets. We focused the subsequent analyses on the ''common'' gene signature class, since we surmised that it could give clues about the transformation process of both the Vav1 À/À DN and CD8 + tumor subpopulations. Standard functional annotation methods did not yield any obvious functional hint (Table S1 ). However, when compared with microarray datasets from other mouse tumors using single-sample gene set enrichment analyses (ssGSEA) and GSEA, we found that the ''common'' gene set shows high similarity to the transcriptome previously described for preleukemic thymocyte populations from Zfp36l1 À/À ;Zfp36l2 À/À mice ( Figures 2B-2D ). Zfp36L proteins antagonize T cell transformation through the binding to and inhibition of translation of Notch1 transcripts (Hodson et al., 2010) . This fact suggested that the loss of Vav1 could be associated with the spurious upregulation of the Notch1 pathway. Buttressing this hypothesis, the ''common'' Vav1 À/À tumor gene signature is also similar to the transcriptome of T-ALL cells generated upon ectopic expression of ICN1 in mouse bone marrow precursors ( Figure 2E ). This resemblance is not due to the activation of programs common to most cancer cells because the Vav1 À/À tumor gene signature does not overlap with the transcriptome of tumor T cells obtained from mice defective in tumor suppressors such as Pten and Cdkn2a ( Figure 2C ). In agreement with these data, we detected high amounts of transcripts commonly upregulated in Notch1-driven T-ALL such as Hes1, Myc, Notch1, and Notch3 in Vav1 À/À DN and CD8 + tumor cells using qRT-PCR ( Figure 2F ). The increase in Notch1 mRNA abundance is seen using primers for both the 5 0 and 3 0 end of its cDNA ( Figure 2F ), indicating enhanced transcription from the WT locus rather than spurious expression of an ICN1-encoding mRNA found in some T-ALL (Jeannet et al., 2010) . The activation of the Notch1 pathway goes in parallel with exacerbated amounts of ICN1 in the tumor cells (Figures 2G and 2H) . Flow cytometry demonstrated the presence of high ICN1 levels in the DN and ISP cells that originate the tumors ( Figure 2I ). Sequencing of genomic DNA fragments from 20 independent tumors indicated that the upregulation of ICN1 is not linked to the emergence of Notch1, Fbxw7, or Pten mutations commonly found in T-ALL (Table S2) .
No statistically significant changes in the amount of ICN1 (Figure 2G ) and ICN1 downstream gene targets ( Figure S3A ) are detected in tumor T cells from DMBA-treated WT mice, indicating that the deregulation of this cascade is intrinsic to the Vav1 deficiency. By contrast, we did find a small increase in the abundance of both ICN1 ( Figure 2I ) and some of its specific downstream transcripts (Hes1, Notch1; Figure 2F ) in both DN populations and unfractionated thymocytes from untreated Vav1 À/À mice, respectively. This upregulation is too weak to be detected in total thymic extracts by immunoblotting ( Figure 2H Figure S3 ; Tables S1 and S2. the Notch1 ligand Delta1 ( Figure 3B ). DN and CD8 + tumor cells preserve the original immunophenotype in these cultures (not shown) and, in the case of CD8 + cells, can regenerate a highly disseminated T-ALL condition when transplanted into recipient WT mice ( Figures 3C-3F ). These tumorigenic properties are further increased upon serial cycles of isolation, culturing, and reinjection into mice ( Figures 3C and 3D) . However, the cells maintain dependency on the Delta1-expressing feeder cells for propagation in culture (not shown). Consistent with these observations, we found that the viability of Vav1 À/À DN and CD8 + tumor cells is impaired by the addition of a g-secretase inhibitor (Compound E) to the cultures ( Figure 3G ). This response is associated with the elimination of ICN1 in those cells (Figure 3G, inset Figure 4A ; for statistics see Figure S4A ) and qRT-PCR (Figure 4B ). By contrast, the amount of the VAV2 and VAV3 mRNA does not change in any of these cells ( Figure 4B Vav1 Modulates ICN1 in a Noncatalytic, Cbl-b-Dependent Manner We next expressed a variety of mouse EGFP-tagged Vav1 mutant proteins ( Figure 5A ) to identify the Vav1 structural domains involved in ICN1 regulation. Using the ability of these proteins to rescue normal HES1 promoter activity when expressed in VAV1 À/À Jurkat cells as a readout, we found that Vav1 proteins with inactivating mutations in the catalytic (E378A, L334A + R375A) and SH2 (G691V) domains exhibit rescuing activities similar to Vav1 WT (Figures 5B and S5A) . By contrast, this rescue activity is abolished when using Vav1 proteins lacking the entire SH3-SH2-SH3 region or bearing inactivating mutations in either the most N-terminal (NSH3, P651L) or C-terminal (CSH3, P833L) SH3 domains (Figures 5B and S5A) . In fact, the expression of these mutant proteins results in the elevation of HES1 promoter activity in VAV1 À/À cells ( Figure 5B ). Further linking the Vav1 SH3
domains to this response, we observed that the expression of the isolated Vav1 SH3-SH2-SH3 fragment also rescues the Vav1 deficiency in these cells (Figures 5B and S5A) . The rescue activity shown by the SH2 mutant version of Vav1 was rather unexpected because, to date, all known activities of Vav family proteins are SH2-and tyrosine phosphorylationdependent (Bustelo, 2014) . To further confirm these results, we decided to assess whether Vav1
WT could repress HES1 promoter activity in Jurkat cells lacking surface expression of the TCRa/b (TCR mut ). Vav1 WT is catalytically inactive in these cells as it cannot be tyrosine phosphorylated by upstream cytoplasmic protein tyrosine kinases (Barreira et al., 2014) . We observed that Vav1 WT shows similar HES1 promoter repression activity in both WT and TCR mut cells ( Figures 5C and S5B ). Furthermore, it exhibits similar activity in unstimulated and TCR-stimulated WT Jurkat cells ( Figure 5C ). By contrast, the Vav1-mediated activation of the nuclear factor of stimulated T cells (NFAT) shows the expected dependence on TCR expression and stimulation status (Figures S5B and S5C) . These results indicate that the Vav1-ICN1 connection can take place in a noncanonical SH2-, TCR-, and tyrosine phosphorylation-independent manner.
The Vav1 SH3 domains can bind to a large variety of proteins (Bustelo, 2014) . However, based on our results indicating a connection of Vav1 with ubiquitinylation of ICN1 ( Figure 4G ), we suspected that one candidate for this regulatory step was the E3 ubiquitin ligase Cbl-b. This protein binds to the Vav1 C terminus via a canonical, proline-rich region (PRR)-mediated interaction (Bustelo et al., 1997) . In favor of this possibility, we found that the shRNA-mediated CBLB knockdown in Jurkat cells phenocopies the effects of the Vav1 deficiency in terms of elevation of ICN1 abundance ( Figures 5D and S5D ) and ICN1 target gene expression ( Figure 5E ). These effects are not seen in Jurkat cells expressing either a scrambled shRNA or CBLB shRNAs that cannot abate Cbl-b expression ( Figures 5D, 5E , and S5D). The expected changes in Cbl-b abundance in these cell lines were demonstrated using both immunoblots on Cbl-b immunoprecipitates ( Figure 5D ) and qRT-PCR ( Figure S5E ). These analyses also demonstrated that the effects induced by CBLB knockdown are not due to the reduction of VAV1 transcript levels phenotype. This led us to investigate whether this pathway was either silenced or downregulated in specific T-ALL subtypes. Given that no mutations in VAV1 and CBLB have been found in the T-ALL cases cataloged so far (http://cancer. sanger.ac.uk/cosmic), we decided to use an in silico approach to identify T-ALL patient subtypes that could fulfill three classification criteria: (1) low abundance of VAV1 transcripts according to expression heatmap analyses; (2) overlap of the transcriptomes with a mouse Vav1 À/À T-ALL-associated gene signature (Table S3) T-ALL cells ( Figures S7C-S7E ). The latter molecular feature is maintained even when using a more stringent gene signature (Table S3 ) in which gene probes directly associated with normal T cell differentiation were not included ( Figures 7D, 7E , and S7F), thus ruling out that this cross-species similarity could be due to the arrest of mouse and human tumor cells in a common, ''cortical''-like differentiation stage. The TLX + T-ALL samples are also the only ones showing an inverse correlation between the abundance of VAV1 and HES1 transcripts (Figures 7F, 7G, and S7G) . This is specific, since the abundance of the HES1 mRNA shows no consistent inverse correlation with transcripts for other Vav family members, Cbl-b, and negative regulators of the Notch1 pathway such as the Zfp36L proteins, Fbxw7, and cyclin c ( Figures 7F, 7G , and S7G). The only exception is the ZFP36L1 transcript, whose abundance is inversely correlated with the amount of HES1 mRNA in one out of the three interrogated datasets ( Figure 7G , dataset #2). Reinforcing these in silico data, we observed that the abundance of endogenous Vav1 is consistently lower in TLX + than in TLX -T-ALL cell lines ( Figures 7H and S7H ). More importantly, Vav1 levels are also lower in tumor cells from a TLX1 + T-ALL patient than in two TLX -T-ALL patient-derived samples ( Figures 7I and S7H ).
The TLX-Mediated Downmodulation of Vav1 Is Required for T-ALL Pathogenesis
The previous results suggested that one of the potential functions of the TLX transcriptional repressor family is to downregulate the Vav1-Cbl-b pathway in TLX + T-ALL cells. Consistent with this hypothesis, in silico analyses of chromatin immunoprecipitation sequencing (ChIP-seq) and ChIP-chip data revealed that VAV1, but not VAV2, has binding sites for TLX1, TLX3, and the associated transcriptional corepressor ETS1 ( Figure S8A ). Figures S8K-S8M ). These results underscore the importance of the downregulation of the Vav1-Cbl-b-Notch1 axis to maintain TLX + T-ALL pathogenesis ( Figure 8O ).
DISCUSSION
Rho GEFs in general, and Vav proteins in particular, have been traditionally linked to protumorigenic pathways (Zandvakili et al., 2017) . Despite this evidence, the roles played by these proteins in cancer cells remain poorly characterized. Our work indicates that these functions can be more variegated than previously anticipated. Thus, we have shown that Vav1 can play a GTPase-independent, tumor-suppressor-like role that mediates Notch1 signaling in T cells. This pathway seems to act by default in immature thymocytes and many T-ALL cells, as determined by the rapid changes in ICN1 abundance recorded when the amounts of either Vav1 or Cbl-b are genetically manipulated. It also seems independent of the mutational status of NOTCH1 and FBXW7, since Vav1 and Cbl-b can alter ICN1 levels even in cells bearing mutant alleles in both loci. Vav1 participates in this pathway in an SH2 domain-and protein tyrosine kinase-independent manner, indicating that it follows regulatory models different from the archetypical, phosphorylation-mediated stimulation of the canonical Vav1-dependent pathways (Bustelo, 2014) . This might explain the need for the transcriptional regulation of the gene in TLX + T-ALL cells, a method of modulation seldom found in Vav1.
The knockout of Vav1 in mice leads to unbalanced Notch1 signaling in immature T cells and the rapid emergence of T-ALL. This transformation step requires additional lesions in other unidentified loci, a result consistent with previous observations indicating that Notch1 signaling elements are not leukemogenic per se unless combined with other predisposing genetic alterations (Chiang et al., 2008) . It is likely that this is also the reason for the longer latencies required for the development of spontaneous T cell tumors previously described in aging Vav1 À/À mice (Ruiz et al., 2009 Gatta et al., 2012; Sanda et al., 2012) .
The downregulation of this Vav1-dependent pathway, via transcriptional repression of the VAV1 rather than loss-of-function mutations, seems to represent a key contributing factor in the pathogenesis of human TLX + T-ALL. This inhibition is mediated by the direct targeting of VAV1 regulatory sequences by the TLX repressor complex. This action does not totally silence VAV1 expression, suggesting that some residual Vav1 activity could still be required to favor, for example, some basal level of stimulation of its catalysis-regulated routes. Alternatively, it might simply reflect the fact that the total depletion of Vav1 is not required to achieve a significant upregulation of ICN1 signaling. This latter idea is consistent with the variations in ICN1 levels and activity observed in T-ALL cells in which the abundance of endogenous Vav1 was manipulated by either expressing or depleting TLX and Vav1. Interestingly, a recent report has shown that TLX proteins have a rather ambivalent and tumorigenic phase-specific relationship with the Notch1 pathway (Durinck et al., 2015) . According to this model, TLX proteins repress the expression of ICN1-regulated genes during the preneoplasic phase to possibly facilitate a thymocyte developmental arrest in an immature, TCR -stage. Subsequently, a hyperactivation of ICN1 signaling seems to be required to bypass this preneoplasic phase and develop the disease. Although not formally corroborated in vivo, this model is interesting because it provides a rational explanation for the high frequency of mutations in the Notch1 pathway typically found in this T-ALL subtype (Neumann et al., 2015) . Assuming this model, we could interpret the elimination of the Vav1-Cbl-b-ICN1 axis in this latter phase as a way to ensure higher levels of ICN1 signaling in fully developed T-ALL cells irrespective of the mutational status of the Notch1 pathway. However, the inhibition of the Vav1-Cbl-b axis in the preneoplasic phase seems at odds with the theoretical need of the TLX-mediated repression of ICN1 target genes that must take place at that stage. One possible explanation for this contradiction is that the upregulation of ICN1, whose activity can be counteracted further downstream by the direct repression of its target genes by TLX, can represent a necessary toll that the transcriptional factor has to pay to make possible the elimination of other Vav1-dependent functions that could be more important for this pretumorigenic stage. For example, it is possible that the elimination of the canonical, Vav1 GEF-dependent pathways could contribute to further amplify or secure the TLX-mediated developmental arrest of thymocytes. This hypothesis is consistent with the known roles of the Vav1-Rac1 pathway in thymocyte development (Bustelo, 2014 T-ALL to identify the gene lesions that cooperate in this leukemogenic process and, at the same time, to verify whether they could include the loss of other tumor-suppressor genes commonly found in TLX + T-ALL that had not been explored in the present work. Could this Vav1 suppressor pathway be active in other Notch family-driven tumors? Available genetic evidence suggests that this could be the case, since some of the VAV1 mutations found in both peripheral T cell leukemia and lung tumors generate C-terminally truncated proteins that cannot interact with Cbl-b. These mutant proteins can be divided into catalytically hyperactive and deficient subsets (J.R.-V. and X.R.B., unpublished data), suggesting that the Vav1 tumor-suppressor and protumorigenic activities can become deregulated independently or concurrently in a tumor-and patient-specific manner. Further work is needed, however, to determine the actual connection of these mutant subgroups with Notch1 signaling and clinically relevant features of cancer patients.
This GTPase-independent Vav1 suppressor pathway will be preserved in cancer cells even under conditions of inhibition of Vav1 catalytic activity. This is therapeutically interesting because, to date, the targeting of the catalytic domains of Rho GEFs is believed to be the most feasible strategy for drug development in the field (Vigil et al., 2010) . By contrast, our results caution against the use of Vav1 depletion avenues, especially in the case of Vav1-dependent tumors positively regulated by Notch1 signals. They also challenge the widely assumed paradigm that links the actions of Rho GEFs with protumorigenic effects in cancer cells, further underscoring the need for the comprehensive characterization of this family using genetic and animal models.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (Cao et al., 2002) . Jurkat J.31.13 (TCR mut ) cells were provided by Dr. B. Alarcó n and described elsewhere (Alcover et al., 1988) . Molt4, CEM, RPMI8402, HPB-ALL, DND41 and Loucy cells were provided by one of the authors of this study (A.B.). ALL-SIL cells were from the DSMZ cell line repository. T-ALL cell lines were cultured in RPMI1640 supplemented with 10% fetal calf serum. In the case of Jurkat cells, they were treated in some cases with antibodies to human CD3 (Cat. No. 217570, Calbiochem) or Compound E as above to stimulate them and inhibit Notch1 cleavage, respectively. the cytogenetic analyses, the TLX status of primary tumor cells was confirmed by qRT-PCR both before and after expansion in immunocompromised mice. For lentiviral infections, thawed cells were cultured for 24 hr as above, infected with lentiviruses encoding either EGFP or the indicated EGFP-Vav1 proteins, centrifuged at 1800 rpm for 90 min without brake at room temperature, and maintained in the above media for 48 hr.
Patient-Derived T-ALL Cells

METHOD DETAILS
Construction of Expression Vectors
To generate the lentiviral vector encoding EGFP-tagged Vav1 WT (pJRV27), the Vav1 cDNA was PCR amplified using the pJLZ52 plasmid as template and the oligonucleotide primers 5'-ATA GGAT CCG CCA CCA TGG AGC TCT GGC GAC AGT GCA CC-3' (forward; BamHI site underlined) and 5'-AGC TAC TCG AGA ATA TTC AGT TAG AAG GGA ACC AGC C-3' (reverse; XhoI site underlined), digested with BamHI and XhoI, and ligated into the pHRSIN vector (provided by A. Rodríguez, Department of Molecular Biology, Madrid Autonomous University, Madrid, Spain). Vectors encoding additional Vav1, Cbl-b and ICN1 mutant proteins are listed in Key Resources Table. Mutations were generated by in situ mutagenesis using the QuikChange mutagenesis kit II (Agilent Technologies). Oligonucleotides used for the mutagenesis steps are listed in Table S4 . All newly generated plasmids were subjected to DNA sequence analysis to confirm both the generation of the proper mutation and the absence of unwanted ones.
Histology
Tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline solution, paraffin-embedded, cut in 2-3 mm sections and stained with hematoxylin and eosin (Sigma). Sections were blindly analyzed by an independent pathologist.
Isolation of Mouse Primary Cells
Single cell suspensions from thymus and spleen were generated by mechanical homogenization of indicated tissues in 3 ml of phosphate-buffered saline solution supplemented with 2% bovine serum albumin plus 0.5 mM EDTA (referred to hereafter as cell extraction buffer), washed once by low-speed centrifugation, resuspended in cell extraction buffer, and subjected to 0.17 M NH 4 Cl lysis to eliminate erythrocytes. Bone marrow cells were collected by flushing cell extraction buffer with the aid of syringe into femur and tibia cavities and, subsequently, processed as above. For intracellular antigen staining, cells were fixed with Cytofix/Cytoperm (Cat. No. 554714, BD Biosciences) for 10 min and stained with PE-labeled antibodies to either TCRb or ICN1 (mN1A, Cat. No. 552768) for 1 hr at room temperature in phosphate buffered saline solution supplemented with 5% fetal bovine serum and 10% saponin. Unless otherwise stated, the antibodies were obtained from BD Biosciences. Antibody-stained cells were analyzed using a FACSAria III flow cytometer (BD Biosciences) and the FlowJo software.
Bioinformatics of Mouse Array Data R version 3.0.3 was used for the statistical analyses along with Perl for text processing. Signal intensity values were obtained from CEL files after robust multichip average (RMA). Differentially expressed genes were identified using linear models for microarray data (Limma). Adjusted P-values for multiple comparisons were calculated applying the Benjamini-Hochberg correction (FDR). Gene Ontology and KEGG pathways enrichment analyses were performed using DAVID. Expression heatmaps were generated using the heatmap3 package. GSEA were performed with described gene sets using gene set permutations (n = 1000) for the assessment of significance and signal-to-noise metric for ranking genes. To evaluate the Vav1 -/-T-ALL-associated gene signature fitness across mouse T cell tumors, the enrichment scores for both the upregulated and downregulated signatures were calculated using ssGSEA. The difference between the two normalized enrichment scores yielded the fit score, a measure of the enrichment and depletion of the upregulated and downregulated signatures, respectively. An empirically determined threshold was set to establish the individual samples with moderate (> 0.25) and high (> 0.40) fitness and Bartlett's, ANOVA and Tukey's HSD tests were performed to identify the T-ALL subtypes with significant enrichment of the signature. The accession codes for the datasets used are E-MEXP-2737 (ArrayExpress database, EMBL-EBI), GSE28823 (Gene Ommnibus Databse, GEO), GSE19499 (GEO database), GSE12948 (GEO databse) and GSE15907 (GEO database).
Determination of mRNA Abundance
Total RNA was extracted from cells using Trizol (Sigma) and analyzed by qRT-PCR using the iScript One-Step RT-PCR kit (BioRad) with SYBR green (BioRad) and the StepOnePlus Real-Time PCR System (Applied BioSystems). Raw qRT-PCR data were analyzed using the StepOne software v2.1 (Applied Biosystems), using the abundance of the endogenous B2m and GAPDH as internal normalization controls for mouse and human samples, respectively. Primers used were 5'-GGCC AGC TGA TAT AAT GGA GAA AA-3' (forward) and 5'-TCC ATG ATA GGC TTT GAT GAC TT-3' (reverse) for mouse Hes1 cDNA; 5'-TGA AGA ACA TGG CCA AGG GTG AGA-3' (forward) and 5'-CTG ATG TGT CAT CCG CCT CAT CCT-3' (reverse) for mouse Notch3 cDNA; 5'-CGA AAC TCT GGT GCA TAA ACT G-3' (forward) and 5'-GAA CCG TTC TCC TTA GCT CTC A-3' (reverse) for mouse Myc cDNA; 5'-GGA CAT GCA GAA CAA CAA GC-3' (forward) and 5'-CAG TCT CAT AGC TGC CCT CA-3' (reverse) for mouse Notch1 cDNA (3'); 5'-TGT GCA GCG TGT TAA TGA CT-3' and 5'-CAG GGC ACC TAC AGA TGA AT-3' for mouse Notch1 cDNA (5'); 5'-GCT ATC CAG AAA ACC CCT CAA-3' (forward) and 5'-CAT GTC TCG ATC CCA GTA GAC GGT-3' (reverse) for mouse B2m cDNA; 5'-TGG TGT CCT TCT GTG TCA GC-3' (forward) and 5'-CTT GAG GCC GAA CTT CTC AC-3' (reverse) for human VAV1 cDNA; 5'-TCA AGG TGC ATC ACA GCT TC-3' (forward) and 5'-TTC AGT GTG CAC TCC TCG AC-3' (reverse) for human VAV2 cDNA; 5'-CTG CAT TTC TGG CTG TTC AA-3' (forward) and 5'-CTG GGA AGA ACA GCT CTT GG-3' (reverse) for human VAV3 cDNA; 5'-TCA ACA CGA CAC CGG ATA AA-3' (forward) and 5'-CCG CGA GCT ATC TTT CTT CA-3' (reverse) for human HES1 cDNA; 5'-GCC GCC TTT GTG CTT CTG TTC-3' (forward) and 5'-CCG GTG GTC TGT CTG GTC GTC-3' (reverse) for human NOTCH1 cDNA; 5'-TTC CAG ATG GCA AAC TCA ATG-3' (forward) and 5'-TAC ATT CTC TCC TTG CCT TCT TTA-3' (reverse) for human CBLB cDNA; 5'-CCT GGC AGT TAT ATC TTC CGG-3' (forward) and 5'-TAC CAC GAT GGG TTC AGT ACC-3' (reverse) for human CBL cDNA; 5'-ATG GCC TTC CGT GTC CCC ACT G-3' (forward) and 5'-TGA GTG TGG CAG GGA CTC CCC A-3' (reverse) for human GAPDH cDNA.
Western Blotting
To determine abundance of proteins, primary thymocytes and cancer cell lines were extensively washed with phosphate-buffered saline solution and lysed in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate, and a mixture of protease inhibitors (Cømplete, Roche). Cellular extracts were precleared by centrifugation at 14,000 rpm for 10 min at 4 C, denatured by boiling in 2x SDS-PAGE sample buffer, separated electrophoretically, and transferred onto nitrocellulose filters using the iBlot Dry Blotting System (Thermofisher). The same separation and transfer was done in the case of immunoprecipitation experiments (see below). Membranes were blocked in 5% bovine serum albumin (Cat. No. A4503, Sigma) in TBS-T (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween-20) for at least 1 hr and then incubated overnight with the appropriate antibodies. Membranes were then washed three times with TBS-T, incubated with the appropriate secondary antibody (1:5,000 dilution, GE Healthcare) for 30 min at room temperature, and washed twice as above. Immunoreacting bands were visualized using a chemoluminescent method (ECL, GE Healthcare). Primary antibodies used included those to the ICN1 fragment (Cat No. 4147, Cell Signaling; 1:1,000 dilution), tubulin a (Cat. No. CP06-100UG, Calbiochem; 1:2,000 dilution), Vav1 DH (homemade, 1:10,000 dilution; used to detect the WT and C-terminally truncated versions of Vav1), Vav1 SH2 (homemade, 1:10,000 dilution; used to detect the Vav1 SH3-SH2-SH3 fragment), HA epitope (Cat. No. MMS-101P, Covance, 1:1,000 dilution), , Cell Signaling; 1:1,000 dilution), GFP (Cat. No. MMS-118P, Covance; 1:2,000 dilution), full length Notch1 (Cat. No. sc-6014, Santa Cruz; 1:1,000 dilution), CD98 (Cat. No. ab108300, Abcam; 1:1,000 dilution), PCNA (Cat. No. ab92552, Abcam; 1:1,000 dilution), GlyRS (Cat. No. sc-98614, Santa Cruz; 1:1,000 dilution), TLX1 (Cat. No. sc-880; Santa Cruz, 1:1,000 dilution), and TLX3 (Cat. No. sc-81990, Santa Cruz, 1:1,000 dilution).
Determination of Promoter Activation
To measure stimulation of the Notch1 pathway using luciferase reporter assays, 2 x 10 7 of exponentially growing Jurkat and HPB-ALL cells were coelectroporated (250 V, 950 mF) with 20 mg of the appropriate expression vectors, the pRL-SV40 vector encoding the Renilla luciferase (5 ng) plus either the pCBF-1 (to measure RBPJk-responsive elements) or pHES1-Luc (to measure HES1 promoter activity) plasmids (10 mg each). When required, electroporations were supplemented with empty vectors to maintain constant the total amount of transfected DNA among samples. After 48 hr, cells were lysed with Passive Lysis Buffer (5x) and luciferase activities determined using the Dual Luciferase Assay System (Cat No. E1960, Promega). To measure activation of the NFAT pathway, 2 x 10 7 of exponentially growing Jurkat cells were coelectroporated with 20 mg of the appropriate Vav1-encoding experimental vectors, the pNFAT-luc reporter vector (10 mg) and pRL-SV40 (5 ng). 36 hr posttransfection, cells were either left non-stimulated or stimulated with antibodies to human CD3 (Cat. No. 217570, UCHT1 clone, Calbiochem, 7,5 mg/ml) for 7 hr and then luciferase activities determined as above. In all cases, the values of firefly luciferase activity obtained in each experimental point were normalized taking into account the activity of the Renilla luciferase obtained in the same sample. In addition, we analyzed aliquots of the same lysates by Western blot to assess the expression of the ectopically expressed proteins in the appropriate experimental sample. Values are represented in the figures as the n-fold change of the experimental sample relative to the HES1 promoter, RBPJk, and NFAT activity shown by control cells (which was given in each case an arbitrary value of 1).
ICN1 Ubiquitinylation
Jurkat cells were transiently transfected with pICN1 and pUb-HA plasmids as above and, after 36 hr, incubated with 50 mM MG132 (Cat No. 474790, Calbiochem) for 6 additional hr in standard cell culture conditions. Cells were then lysed in 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1% Triton X-100, 1 mM EGTA, 10 mM Na 3 VO 4 , 100 mM NaF, Cømplete, and 10 mM MG132 at 4 C. Upon elimination of cell debri by centrifugation, cellular extracts were incubated for 2 hr at 4 C with anti-HA (1:100 dilution) followed by 1 hr of incubation with Gammabind G-Sepharose beads (GE Healthcare) at 4 C. After washes, immunocomplexes were subjected to Western blot analyses as indicated above.
In Vivo g-Secretase Activity 3 3 10 7 exponentially growing Jurkat cells were collected in ice-cold phosphate-buffered saline solution and pelleted at 5,000 rpm for 5 min. The pellet was homogenized in 500 ml of g-secretase assay buffer (20 mM HEPES (pH 7.5), 150 mM KCl, 2 mM EGTA, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate and Cømplete) and passed through a 27 G needle five times using a 1 ml syringe. The resulting homogenate was cleared at 45,000 rpm for 1 hr at 4 C. The pellet from this step was resuspended in 500 ml of g-secretase assay buffer and passed through a 27 G needle five times on ice. The suspension was cleared at 45,000 rpm for 1 hr at 4 C and, upon elimination of the resulting supernatant, the pellet was resuspended in 75 ml of g-secretase assay buffer supplemented with 1% CHAPSO and subjected to rotation for 2 hr at 4 C. The solubilized fraction from that step was centrifuged at 45,000 rpm for 1 hr at 4 C and the resulting supernatant considered the membrane-enriched fraction to be used in the g-secretase activity determination. To this end, we monitored changes in the fluorescence emission of a fluorogenic peptide containing the amyloid precursor protein g-secretase cleavage site (Cat. No. 565764, Calbiochem) upon an incubation with either cellular membranes or bovine serum albumin (negative control) for 16 hr at 37 C in a 5% CO 2 atmosphere (Farmery et al., 2003) . To demonstrate bona fide g-secretase activity, we incubated in parallel aliquots from the same samples with 200 nM Compound E. In all cases, fluorescence changes (excitation max.: z355 nm; emission max.: z440 nm) in the incubation mixture were measured using a microplate reader (Ultraevolution, Tecan).
Immunoprecipitation Experiments
In the case of endogenous proteins, 5 3 10 7 exponentially growing Jurkat cells were lysed in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate and Cømplete. Upon elimination of cell debri by centrifugation, cellular extracts were incubated for 2 hr at 4 C with primary antibodies. In some cases, cells were treated with 5 mM ivermectin (Cat. No. I8898, Sigma) and 50 mM MG132 for 4 hr prior to the lysis step. Upon elimination of cell debri by centrifugation, cellular extracts were incubated for 2 hr at 4 C with antibodies to ICN1 (Cat No. ab52301, Abcam; 1:100 dilution). In the case of ectopically expressed proteins, 2 3 10 6 of exponentially growing Jurkat cells were transfected with 20 mg of the appropriate mammalian expression vector (diluted in 2 ml of R buffer; Cat No. MPK10096, Life Technologies) using two 20-msec electroporation cycles at 1.7 mV in the Neon system (Life Technologies). Electroporated cells were then maintained in standard culture media for 36 hr and lysed in 10 mM TrisHCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate and Cømplete. Upon elimination of cell debri, cellular extracts were incubated for 2 hr at 4 C with primary antibodies. Those included antibodies to HA (Cat. No. MMS-101P, Covance, 1:100 dilution), Cbl-b (Cat. No. sc-1435, Santa Cruz, 1:200 dilution) , and ICN1 (Cat No. ab52301, Abcam; 1:100 dilution). In all cases, immunocomplexes were collected with Gammabind G-Sepharose beads (GE Healthcare), washed three times in the buffer used for cell lysis, resuspended in SDS-PAGE buffer, boiled for 5 min, and subjected to immunoblot analysis as indicated above.
shRNA-Mediated Transcript Knockdowns
To knockdown VAV1, the indicated T-ALL cell lines were infected with lentiviruses encoding either scrambled (TR1. . To inactivate TLX1, ALL-SIL cells were transduced with lentiviral particles encoding a TLX1-directed shRNA (TRCN0000014995; Sigma). To knockdown TLX3, HBP-ALL cells were infected with lentiviruses encoding a TLX3-specific shRNA (TRCN0000018030; Sigma). In all cases, cells were subjected to either long-term (15 days; Jurkat, CEM, and Molt4) or short-term (5 days; ALL-SIL, HPB-ALL) puromycin selection. Proper transcript knockdown was assessed using immunobloting and/or qRT-PCR.
Subcellular Fractionation
Jurkat cells (3 3 10 7 ) were resuspended in 1 ml of hypotonic lysis buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate and Cømplete) and passed through a 25 G needle 10 times using a 1 ml syringe. Cells were then centrifuged at 14,000 rpm for 10 min at 4 C. The pellet (P1) from this step was resuspended in 500 ml of hypotonic lysis buffer supplemented with 1% Triton X-100 and subjected to centrifugation at 3,000 rpm for 10 min at 4 C to eventually collect the resulting supernatant and pellet fractions that were considered, respectively, as the nuclear and insoluble compartments. The supernatant from the first centrifugation step (S1) was diluted to a final volume of 5 ml with the hypotonic lysis buffer and subjected to high-speed (60,000 rpm) centrifugation for 1 hr at 4 C using polycarbonate centrifuge tubes (Cat. No. 349622, Beckman Coulter). The supernatant and pellet fractions from this step were considered as the cytosolic and membrane compartment, respectively. All fractions were resuspended in SDS-PAGE buffer, boiled for 5 min, and subjected to immunoblot analysis as indicated above. In the case of experiments to check the subcellular distribution of ICN1 ubiquitinylation, Jurkat cells were transiently transfected with the pICN1 and pUb-HA expression plasmids (see section above) and, 48 hr later, subjected to the subcellular fractionation procedure indicated for nontransfected cells.
Bioinformatics of Human T-ALL Microarray Data
Expression heatmaps were generated as above, using GEO datasets GSE62156 (dataset 1), GSE28703 (dataset 2) and GSE26713 (dataset 3). In overall, these arrays include a total of 240 patients, either adult (dataset 1 and 2; n = 64 and 52, respectively) or pediatric (dataset 3, n = 124). TLX status in those samples was determined according to genome chacterization (dataset 1 and 3). However, since these data were missing in dataset 2, we defined as ''TLX + '' in this case the samples that showed high abundance of either TLX1 or TLX3 trancripts according to expression heatmap analyses.
To carry out ssGSEA, we first generated a shared gene signature composed of genes found deregulated in tumor cells from both Vav1 -/-(this work) and Zfp36l1 -/-;Zfp36l2 -/-(ArrayExpress E-MEXP-2737) knockout mice. To this end, we performed a GSEA on the Vav1 -/-expression dataset using as gene set the differentially expressed genes (absolute fold change > 2) in Zfp36l1 -/-;Zfp36l2 -/-knockout mouse-derived microarray-derived samples. The analysis of the up-and downregulated gene sets yielded a series of genes belonging to the leading edge (core enrichment), which was referred as the ''shared Vav1 (Table S3 ). This signature was used to test possible hits with array data from T-ALL dataset 1 (GEO GSE62156) using both ssGSEA and GSEA (Figures S7C-S7E ). Subsequently, it was further refined to eliminate deregulated genes that could be associated with just a normal undifferentiated state of T cells. To generate this ''tumor-specific'' signature, we selected genes that, according to GSEA performed with T-ALL dataset 1 and a T-cell development microarray dataset (GEO GSE15907), were not associated with the undifferentiated state of ''healthy'' T lymphocytes ( Figure S7F and Table S3 ). The presence of this ''tumor-specific'' Vav1
-/-gene signature in samples from T-ALL datasets 1, 2 and 3 was determined using ssGSEA as described above.
Expression heatmaps were generated as indicated above for mouse array analyses. Expression correlation matrices were calculated for the indicated mRNA pairs using the corrplot package (http://CRAN.R-project. org/package=corrplot) and the datasets 1, 2 and 2 indicated above. Correlations were considered as statistically significant when the Pearson correlation coefficient corresponded to a p value below 0.05. Depending upon the total number of samples in each dataset, this significance was achieved when the absolute value for the Pearson correlation coefficient was above 0.39 (dataset 1), 0.33 (dataset 2) and 0.28 (dataset 3).
Transcriptional Factor Binding to Regulatory Gene Sequences
In the case of Chip-seq analyses, raw data mapping and peak calling were performed with Bowtie and MACS1.4, selecting peaks with p value % 10 À5 . hg18 coordinates were converted to the hg19 assembly using the LiftOver utility of the UCSC Genome Browser Tools. Wig files were converted to bed format using the wig2bed utility of the BEDOPS Suite. Visualization of data was performed in R using the Gviz package. The accession codes for the datasets used are GSE62144 (for TLX1) and GSE51800 (for Ets1 and Runx1).
In the case of ChIP-chip analyses with TLX1 and TLX3, we used the dataset reported before (Della Gatta et al., 2012) . ChIP-chip Significance Analysis was used, applying a significance cutoff of p % 10 -9 to select statistically significant peaks.
Lentiviral-Mediated Expression of EGFPs in T-ALL Cells
For EGFP-Vav1 WT overexpression, T-ALL cells were infected with lentiviral particles encoding either EGFP or the indicated EGFPVav1 fusions by spinoculation of viral supernatants produced in HEK293T cells at 1,800 rpm for 90 min without brake at room temperature. Proper protein expression was assessed using flow cytometry.
Determination of Cell Proliferation HPB-ALL, Jurkat, Molt4, and Loucy cells were transfected with the indicated vectors using the Neon system. ALL-SIL cells were infected with either EGFP-or EGFP-Vav1 WT -encoding lentiviruses. At the indicated time points, proliferation was measured in all cases using the 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) method. To this end, the culture medium of each well was replaced by 100 ml of the MTT solution (0.5 mg/ml) made in phosphate-buffered saline solution. After 2 hr at 37 C in a 5% CO 2 atmosphere, 100 ml of DMSO were added per well to dissolve the formazan crystals formed and the absorbance at 570 nm measured 15 min later using the Ultraevolution reader.
Determination of Apoptotic Rates
Cells were harvested either 48-96 (in the case of HPB-ALL, ALL-SIL, Loucy and Jurkat cells) or 48 (in the case of patient-derived T-ALL cancer cells) hr after the transfection or viral transduction step respectively, stained using the Annexin V-fluorescein propidium isothiocyanate detection kit (Immunostep), and apoptosis determined in the population of GFP-gated cells using flow cytometry.
QUANTIFICATION AND STATISTICAL ANALYSIS Statistics
Tukey's HSD tests were used to identify those groups showing differential enrichment of the indicated signatures. Student's t and Mann-Whitney tests were used to analyze results from wet lab experiments as indicated in the figure legends. Statistical analyses were carried out using the R (in the case of Tukey's HSD tests) and GraphPad Prism software (version 6.0; in the case of both Student's t and Mann-Whitney tests). The number of biological replicates (n) and significance for each experiment can be found in the figure legend of the experiment as well as the results section of this document.
DATA AND SOFTWARE AVAILABILITY
Data Resource
Microarray data reported in this paper has been deposited in the GEO database (https://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE80490. . The black asterisk in the Cbl-b panel labels the GlyRS (Glycyl-tRNA synthetase) protein band from the previous immunoblot performed in the same filter. Red asteriscs label panels that have been generated using electrophoresed lysates transferred to an independent nitrocellulose filter. (C) Detection of ubiquitinylated, ectopically expressed ICN1 (top panel) and endogenous proteins (second panel from top) in indicated Jurkat cells (top) and subcellular fractions (bottom). As control, aliquots of the lysates used in the above immunoprecipitations were analyzed by immunoblot to detect the amount of ectopically expressed ICN1 (third panel from top) and the indicated subcellular fractionation controls (fourth to eight panels from top). In B and C, similar data were obtained in an additional independent experiment. Quality of the fractionation procedure was demonstrated using antibodies to membrane (CD98), cytoplasmic (tubulin, GlyRS), and nuclear (PCNA) markers. All blots were generated using antibodies to the indicated proteins. The only exception is the detection of total ubiquitinylated proteins (C, second panel from top), which was carried out using antibodies to the HA epitope. WT in endogenous ICN1 abundance (K), proliferation (L) and apoptosis (M) of indicated cells (top). The experiments were carried out either the absence (-ICN1) or presence (+ICN1) of ectopically expressed ICN1 (n = 3). In panels B and H to M, data represent the mean ± SEM. **, p ≤ 0.01; ***, p ≤ 0.001 (Student's t tests). 
